Aratana Therapeutics revenue was $35.41 m in FY, 2018

## Founding Date | 2010 |

## Total Funding | $76.8 m |

## Investors | Avalon Ventures, MPM Capital, Cultivian Ventures, Kansas Bioscience Authority |

Aratana Therapeutics is a subsidiary of Elanco

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Revenue | 123.0k | 767.0k | 678.0k | 38.6m | 25.6m | 35.4m |

| 524% | (12%) | 5586% | |||

## Cost of goods sold | 108.0k | 333.0k | 365.0k | 3.1m | 16.4m | 6.8m |

## Gross profit | 15.0k | 434.0k | 313.0k | 35.4m | 9.2m | 28.6m |

| 12% | 57% | 46% | 92% | 36% | 81% |

## R&D expense | 10.9m | 20.0m | 25.0m | 30.5m | 15.1m | 6.9m |

## General and administrative expense | 8.6m | 17.9m | 19.8m | 27.3m | 28.9m | 28.8m |

## Operating expense total | 19.9m | 42.0m | 89.8m | 66.2m | 53.6m | 40.5m |

## Depreciation and amortization | 380.0k | 1.9m | 1.5m | 379.0k | 350.0k | 517.0k |

## EBIT | (19.9m) | (41.6m) | (89.5m) | (30.8m) | (44.5m) | (11.9m) |

| (16149%) | (5425%) | (13200%) | (80%) | (174%) | (34%) |

## Interest expense | 121.0k | 1.4m | 3.7m | 2.8m | 3.1m | 2.8m |

## Interest income | 75.0k | 123.0k | 189.0k | 385.0k | 449.0k | 666.0k |

## Pre tax profit | (19.7m) | (40.3m) | (85.8m) | (33.6m) | (47.5m) | (14.7m) |

## Income tax expense | (15.5m) | (1.4m) | (1.7m) | |||

## Net Income | (4.3m) | (38.8m) | (84.1m) | (33.6m) | (47.5m) | (14.7m) |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Cash | 41.1m | 9.8m | 26.8m | 87.3m | 66.9m | 41.4m |

## Accounts Receivable | 352.0k | 60.0k | 87.0k | 2.4m | 2.2m | |

## Prepaid Expenses | 274.0k | 900.0k | 1.5m | 1.6m | 1.8m | |

## Inventories | 55.0k | 427.0k | 1.3m | 11.1m | 13.6m | 11.4m |

## Current Assets | 48.5m | 99.9m | 89.0m | 101.5m | 85.2m | 58.1m |

## PP&E | 98.0k | 620.0k | 2.6m | 1.9m | 1.2m | 693.0k |

## Goodwill | 20.8m | 41.4m | 39.8m | 39.4m | 41.3m | 40.8m |

## Total Assets | 115.5m | 207.9m | 147.1m | 151.4m | 135.2m | 106.4m |

## Accounts Payable | 2.3m | 1.5m | 1.4m | 7.4m | 7.5m | 911.0k |

## Short-term debt | 8.6m | 17.3m | ||||

## Current Liabilities | 16.9m | 9.5m | 5.7m | 34.7m | 35.5m | 5.6m |

## Long-term debt | ||||||

## Total Debt | 17.3m | |||||

## Total Liabilities | 29.5m | 26.1m | 45.5m | 61.0m | 55.1m | 5.6m |

## Common Stock | 23.0k | 34.0k | 35.0k | 43.0k | 48.0k | |

## Additional Paid-in Capital | 112.5m | 255.0m | 263.9m | 286.9m | 321.6m | 350.7m |

## Retained Earnings | (68.0m) | (152.0m) | (185.6m) | (233.3m) | (241.2m) | |

## Total Equity | 86.0m | 181.8m | 101.6m | 90.4m | 80.1m | 100.8m |

## Debt to Equity Ratio | 0.2 x | |||||

## Debt to Assets Ratio | 0.1 x | |||||

## Financial Leverage | 1.3 x | 1.1 x | 1.4 x | 1.7 x | 1.7 x | 1.1 x |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Net Income | (4.3m) | (38.8m) | (84.1m) | (33.6m) | (47.5m) | (14.7m) |

## Depreciation and Amortization | 395.0k | 2.0m | 1.8m | 991.0k | 1.2m | 990.0k |

## Accounts Receivable | (102.0k) | 281.0k | (27.0k) | (2.3m) | 202.0k | |

## Inventories | (372.0k) | (879.0k) | (15.0m) | (3.2m) | (499.0k) | |

## Accounts Payable | 1.5m | (1.1m) | (117.0k) | 6.2m | 62.0k | (6.5m) |

## Cash From Operating Activities | (16.2m) | (32.2m) | (38.5m) | (11.3m) | (38.2m) | (11.3m) |

## Purchases of PP&E | (94.0k) | (471.0k) | (2.2m) | (72.0k) | (1.0k) | |

## Cash From Investing Activities | (29.2m) | (100.1m) | 33.7m | 57.3m | (5.8m) | (493.0k) |

## Long-term Borrowings | (3.5m) | (36.5m) | ||||

## Dividends Paid | ||||||

## Cash From Financing Activities | 72.5m | 101.0m | 21.9m | 14.6m | 23.5m | (13.7m) |

## Net Change in Cash | 27.1m | (31.3m) | 16.9m | 60.6m | (20.4m) | (25.4m) |

## Interest Paid | 357.0k | 942.0k | 1.1m | 2.9m | 3.0m | 4.0m |

USD | Q2, 2013 |
---|---|

## Debt/Equity | -0.1 x |

## Debt/Assets | 0.1 x |

## Financial Leverage | -0.8 x |